We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Labeling for proposed ready-to-use products that contain a range of drug strengths in a single container should contain instructions for determining the correct dose to be administered based on a patient’s weight or body surface area (BSA), according to a new FDA draft guidance.